Payment overview · 2025
General Payments
$354.88
20 reported records · 12 companies
Healthcare provider profile · identity verified
James D. Steckelberg, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SYRACUSE, NE · NPI 1962419713
Verified facts
What the public records show
CMS Open Payments records show James D. Steckelberg, M.D. received $354.88 in general payments during 2025 across 20 reported records.
Lundbeck LLC accounted for 20.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Kerendia by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lundbeck LLC | Unresolved — no canonical attribution shown | $71.10 | 20.0% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $45.56 | 12.8% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.43 | 9.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.08 | 9.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.97 | 9.3% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $32.24 | 9.1% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $23.58 | 6.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.83 | 6.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.33 | 4.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.96 | 4.2% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.21 | 4.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.59 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $316.34 | 19 |
| Education | $38.54 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $103.34 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $45.56 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.43 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $33.08 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $23.58 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.83 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.33 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
148 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 752 | 178 |
| Levothyroxine Sodium | Levothyroxine Sodium | 739 | 121 |
| Amlodipine Besylate | Amlodipine Besylate | 501 | 118 |
| Furosemide | Furosemide | 455 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 388 | 88 |
| Losartan Potassium | Losartan Potassium | 387 | 80 |
| Omeprazole | Omeprazole | 375 | 74 |
| Potassium Chloride | Potassium Chloride | 357 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 316 | 74 |
| Eliquis | Apixaban | 299 | 48 |
| Lisinopril | Lisinopril | 297 | 70 |
| Metformin Hcl | Metformin Hcl | 292 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 239 | 58 |
| Carvedilol | Carvedilol | 234 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 228 | 39 |
| Gabapentin | Gabapentin | 224 | 53 |
| Tramadol Hcl | Tramadol Hcl | 196 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 174 | 45 |
| Donepezil Hcl | Donepezil Hcl | 172 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 170 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 40 |
| Allopurinol | Allopurinol | 149 | 36 |
| Farxiga | Dapagliflozin Propanediol | 148 | 19 |
| Myrbetriq | Mirabegron | 141 | 14 |
| Montelukast Sodium | Montelukast Sodium | 140 | 30 |
| Pregabalin | Pregabalin | 136 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 126 | suppressed |
| Xarelto | Rivaroxaban | 125 | 19 |
| Mirtazapine | Mirtazapine | 120 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 116 | 27 |
| Jardiance | Empagliflozin | 114 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 113 | 19 |
| Alprazolam | Alprazolam | 112 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 111 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 24 |
| Meloxicam | Meloxicam | 108 | 27 |
| Trulicity | Dulaglutide | 106 | 13 |
| Prednisone | Prednisone | 105 | 65 |
| Sertraline Hcl | Sertraline Hcl | 101 | 22 |
| Spironolactone | Spironolactone | 97 | 23 |
| Memantine Hcl | Memantine Hcl | 96 | 12 |
| Simvastatin | Simvastatin | 87 | 21 |
| Warfarin Sodium | Warfarin Sodium | 83 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 17 |
| Mounjaro | Tirzepatide | 78 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 78 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 77 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 22 |
| Metformin Hcl Er | Metformin Hcl | 72 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | 14 |
| Ezetimibe | Ezetimibe | 65 | 12 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 62 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 23 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 58 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 11 |
| Propranolol Hcl | Propranolol Hcl | 57 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 53 | 53 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 53 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 15 |
| Januvia | Sitagliptin Phosphate | 52 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 51 | suppressed |
| Finasteride | Finasteride | 49 | 14 |
| Clonazepam | Clonazepam | 48 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 48 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 47 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 46 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 45 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | suppressed |
| Famotidine | Famotidine | 44 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 43 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Torsemide | Torsemide | 40 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Ibuprofen | Ibuprofen | 38 | suppressed |
| Ozempic | Semaglutide | 38 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 36 | 36 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 34 | suppressed |
| Cephalexin | Cephalexin | 33 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 28 |
| Estradiol | Estradiol | 32 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Sucralfate | Sucralfate | 31 | suppressed |
| Novolog Flexpen | Insulin Aspart | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 11 |
| Linzess | Linaclotide | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Vascepa | Icosapent Ethyl | 27 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Nystatin | Nystatin | 24 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 23 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 19 |
| Methenamine Hippurate | Methenamine Hippurate | 22 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 21 | suppressed |
| Kerendia | Finerenone | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 13 |
| Cefdinir | Cefdinir | 20 | 16 |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 20 | 20 |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Budesonide | Budesonide | 19 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 18 |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Rexulti | Brexpiprazole | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Roflumilast | Roflumilast | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Trospium Chloride | Trospium Chloride | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Digoxin | Digoxin | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 13 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Trandolapril | Trandolapril | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Quviviq | Daridorexant Hcl | 11 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $354.88 · 20 records | Lundbeck LLC | AIRSUPRA, Dexcom G6 Transmitter, EVENITY, Kerendia, LEQVIO, NEXLETOL, QULIPTA, REXULTI, UBRELVY, VRAYLAR, WATCHMAN FLX, Wegovy, XIFAXAN | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error